menu
    • menu
    [{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Ultimovacs","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell & Gene Therapy","year":"2024","type":"Merger","leadProduct":"ZI-MA4-1","moa":"MAGE-A4","graph1":"Oncology","graph2":"Preclinical","graph3":"Zelluna Immunotherapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelluna Immunotherapy \/ Zelluna Immunotherapy","highestDevelopmentStatusID":"4","companyTruncated":"Zelluna Immunotherapy \/ Zelluna Immunotherapy"},{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ZI-MA4-1","moa":"MAGE-A4","graph1":"Oncology","graph2":"Preclinical","graph3":"Zelluna Immunotherapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelluna Immunotherapy \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Zelluna Immunotherapy \/ Undisclosed"},{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Zelluna Immunotherapy","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zelluna Immunotherapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelluna Immunotherapy \/ Zelluna Immunotherapy","highestDevelopmentStatusID":"4","companyTruncated":"Zelluna Immunotherapy \/ Zelluna Immunotherapy"},{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Lion TCR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zelluna Immunotherapy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelluna Immunotherapy \/ Lion TCR","highestDevelopmentStatusID":"1","companyTruncated":"Zelluna Immunotherapy \/ Lion TCR"},{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ZI-MA4-1","moa":"MAGE-A4","graph1":"Oncology","graph2":"Preclinical","graph3":"Zelluna Immunotherapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zelluna Immunotherapy \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Zelluna Immunotherapy \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Zelluna Immunotherapy

    Menu

    Zelluna Immunotherapy

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZI-MA4-1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for F...

                            Details : ZI-MA4-1 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Preclinical clinical studies for the treatment of Neoplasms.

                            Product Name : ZI-MA4-1

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 09, 2025

                            Lead Product(s) : ZI-MA4-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZI-MA4-1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zelluna Finalizes Manufacturing for TCR-NK Therapy ZI-MA4-1 Clinical Entry

                            Details : ZI-MA4-1 is a TCR-NK off-the-shelf cell therapy developed by Zelluna Immunotherapy AS targeting solid tumors, specifically those expressing MAGE-A4.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 22, 2025

                            Lead Product(s) : ZI-MA4-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZI-MA4-1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Ultimovacs

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Ultimovacs Combines Business with Zelluna, Plans Private Placement Launch

                            Details : The combined company will advance the development of ZI-MA4-1. It is being evaluated in the preclinical studies for the treatment of NSCLC, ovarian cancers.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 17, 2024

                            Lead Product(s) : ZI-MA4-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Ultimovacs

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Lion TCR

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zelluna Collaborates with Lion TCR to Develop TCR-NK Cell Therapies to Treat Virally Induced Cancers

                            Details : The collaboration will initially focus on the development of TCR-NK products targeting Hepatitis B Virus (HBV) which is a leading cause of liver cancer and has a high unmet need for efficient treatment options.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 24, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Lion TCR

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Zelluna Immunotherapy

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Karolinska Institutet

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zelluna Immunotherapy collaborates with Karolinska Institutet

                            Details : The collaboration will support a multi-year research program with Dr. Evren Alici, that aims to develop next generation TCR guided NK cells.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 12, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Karolinska Institutet

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth